FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washing

D O 00E40	
aton, D.C. 20549	0145.4
, ·	∥ OMB A
	ONID /

APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MCGIRR DAVID W J						2. Issuer Name <b>and</b> Ticker or Trading Symbol X4 Pharmaceuticals, Inc [ XFOR ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
		rst) (EUTICALS, IN				Date of Earliest Transaction (Month/Day/Year) 6/02/2021										(give title		Other (s below)	
(Street) BOSTON	N M	A (	02134 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
		Tab	le I - Non-	Deriva	ative	Sec	uritie	s Ac	quire	d, Di	sposed (	of, or Be	neficia	lly O	wned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,			Cod 8)	Transaction Code (Instr. 8)		(4) 0	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		s ally following I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Dwnership Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code			of		6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			ivative urity itr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					ode	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares	nber					
Stock Option (right to buy)	\$9.5	06/02/2021			A		6,000		(1)		06/02/2031	Common Stock	6,000	\$9	9.5	6,000		D	

## **Explanation of Responses:**

1. 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such

## Remarks:

Derek M. Meisner, attorney-in-

<u>fact</u>

\*\* Signature of Reporting Person Date

06/02/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.